Guided Therapeutics, Inc. (OTCBB & QTCQB: GTHP) announced that it received a $244,479 Federal grant to advance its LightTouch™ Cervical Scanner, currently under FDA review for market approval.
"We are pleased to receive the grant and the recognition it brings to our LightTouch non-invasive cervical disease detection technology," said Mark L. Faupel, Ph.D., President and CEO of Guided Therapeutics. "The LightTouch represents a possible significant breakthrough in early cancer detection, when the disease is most treatable, potentially improving cancer care outcomes in cervical cancer, while reducing the costs associated with unnecessary biopsies."
"As much as $6 billion is spent annually in the United States to diagnose true cervical disease from all the false positive and ambiguous cervical cancer screening tests. Using non-invasive technology, Guided Therapeutics uses light to painlessly determine if there is cervical disease present and results are immediately available," wrote, U.S. Senator Johnny Isakson (R-GA), in support of the LightTouch.
The U.S. Treasury's qualifying therapeutic discovery projects program grant is the seventh Federal award, totaling more than $6 million, given to support the development of the LightTouch.
Gut health and diet: Keys to treating acne, alopecia, and dermatitis